Table 2.
Number and Sources of Comments Received by the ISSCR on Draft Guidelines
| Countries (Number of Comments Received) | |||
| Argentina (1) | Australia (3) | Austria (1) | Brazil (1) |
| Canada (2) | China (1) | France (1) | Germany (5) |
| India (1) | Iran (1) | Italy (1) | Israel (1) |
| Japan (6) | Korea (1) | Netherlands (2) | Norway (1) |
| Singapore (1) | Spain (2) | Sweden (4) | Turkey (1) |
| United Kingdom (9) | United States (32) | Regional/International (7) | |
| Many comments represent the input from multiple individuals or entities. | |||
| Consortia, Societies/Networks, Organizations | |||
| American Society for Reproductive Medicine | American Society for Transplantation | ||
| American Society of Transplant Surgeons | Associação Brasileira de Terapia Celular (Brazilian Association for Cell Therapy) | ||
| Australian Therapeutic Goods Administration | Austrian Society for Regenerative Medicine | ||
| California Institute for Regenerative Medicine | Canadian Institutes of Health Research | ||
| Catholic Organizations New York | Centre of Genomics and Policy at McGill University | ||
| Coriell Institute for Medical Research | European Medicines Agency | ||
| German Stem Cell Network | Health Research Authority, United Kingdom | ||
| Human Fertilization and Embryology Authority, United Kingdom | International Alliance of Patients’ Organizations | ||
| International Society for Experimental Hematology | International Stem Cell Forum Ethics Working Party | ||
| International Society for Cell Therapy | Japanese Society for Regenerative Medicine | ||
| Korean Society for Stem Cell Research | Miltenyi Biotech | ||
| Nature Magazine/NPG | Organization for Economic Co-operation and Development | ||
| RUCDR Infinite Biologics | Secretariat on Responsible Conduct of Research, Canada | ||
| Spanish Agency on Medicines and Medical Devices | Stem Cell Network North Rhine-Westphalia | ||
| StemBANCC | |||
Publication of the draft guidelines was announced widely and request for comment was made to 110 individuals/entities. Comments on the draft guidelines were received from a wide range of individual and organizational stakeholders from around the world. Comments were thoughtfully reviewed by the ISSCR task force. Listing does not constitute endorsement of the ISSCR Guidelines for Stem Cell Research and Clinical Translation.